Insights into HIV-1 pathogenesis through drug discovery: 30 years of basic research and concerns for the future

HIV and AIDS Review

Volumn 10, Issue 4, 2011, Pages 91-98

  Schader, Susan M ^a,b   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

AIDS; Antiretroviral drugs; Drug resistance; HIV; Microbicides; Pre exposure prophylaxis

Indexed keywords

ADEFOVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; MICROBICIDE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

BLOODSTREAM INFECTION; DEVELOPING COUNTRY; DISEASE COURSE; DRUG EXPOSURE; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; REVIEW; SEXUAL BEHAVIOR; SEXUALITY; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

EID: 83255187129     PISSN: 17301270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hivar.2011.09.003     Document Type: Review

References (106)

1. CDC, Pneumocystis pneumonia - Los Angeles, MMWR (1981) 250-252.
2. H. Masur, M.A. Michelis, J.B. Greene, I. Onorato, R.A. Stouwe, R.S. Holzman, et al., An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction, N. Engl. J. Med. 305 (1981) 1431-1438. (Pubitemid 12240077)
3. M.S. Gottlieb, R. Schroff, H.M. Schanker, J.D. Weisman, P.T. Fan, R.A. Wolf, et al., Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency, N. Engl. J. Med. 305 (1981) 1425-1431. (Pubitemid 12240076)
4. L. Altman, Rare cancer seen in 41 homosexuals, New York Times (1981).
5. G.M.H. Shearer, U. Is sperm immunosuppressive in homosexuals and vasectomized men? Immunol. Today 3 (1982) 153-154.
6. R.M. du Bois, M.A. Branthwaite, J.R. Mikhail, J.C. Batten, Primary Pneumocystis carinii and cytomegalovirus infections, Lancet 2 (1981) 1339. (Pubitemid 12180396)
7. CDC, Kaposi's sarcoma (KS), Pneumocystis pneumonia (PCP), and other opportunistic infections (01): case reported to CDC as of July 8th 1982, MMWR 31 (1982), 507-508, 513-514.
8. CDC, Opportunistic infections and Kaposi's sarcome among Haitians in the United States, MMWR 31 (1982), 351-354, 360-361.
9. CDC, Epidemiological notes and reports Pneumocystis carinii pneumonia among persons with hemophilia A, MMWR (1982) 365-367.
10. CDC, Epidemiological notes and reports immunodeficiency among female sexual partners of males with Aquired Immunodeficiency Syndrome, MMWR 31 (1983) 697-698.
11. P. Piot, T.C. Quinn, H. Taelman, F.M. Feinsod, K.B. Minlangu, O. Wobin, et al., Acquired immunodeficiency syndrome in a heterosexual population in Zaire, Lancet 2 (1984) 65-69. (Pubitemid 14085127)
12. WHO, Acquired Immune Deficiency Syndrome Emergencies, Report of a WHO Meeting, 1983, Geneva.
13. CDC, Current trends prevention of Acquired Immune Deficiency Syndrome (AIDS): report of interagency recommendations, MMWR (1983) 101-103.
14. F. Barre-Sinoussi, J.C. Chermann, F. Rey, M.T. Nugeyre, S. Chamaret, J. Gruest, et al., Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS), Science 220 (1983) 868-871. (Pubitemid 13080157)
15. J.L. Marx, Strong new candidate for AIDS agent, Science 224 (1984) 475-477.
16. M. Popovic, M.G. Sarngadharan, E. Read, R.C. Gallo, Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS, Science 224 (1984) 497-500. (Pubitemid 14134740)
17. J. Coffin, A. Haase, J.A. Levy, L. Montagnier, S. Oroszlan, N. Teich, et al., What to call the AIDS virus? Nature 321 (1986) 10.
18. UNAIDS, UNAIDS 2010 Factsheet, UNAIDS, 2010.
19. UNAIDS, UNAIDS Report on the Global AIDS Epidemic, 2010.
20. B.J. Poiesz, F.W. Ruscetti, A.F. Gazdar, P.A. Bunn, J.D. Minna, R.C. Gallo, Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma, Proc. Natl. Acad. Sci. U. S. A. 77 (1980) 7415-7419. (Pubitemid 11131140)
21. M. Yoshida, I. Miyoshi, Y. Hinuma, Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease, Proc. Natl. Acad. Sci. U. S. A. 79 (1982) 2031-2035. (Pubitemid 12088563)
22. M.G. Sarngadharan, M. Popovic, L. Bruch, J. Schupbach, R.C. Gallo, Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS, Science 224 (1984) 506-508. (Pubitemid 14134743)
23. L. Ratner, R.C. Gallo, F. Wong-Staal, HTLV-III, LAV, ARV are variants of same AIDS virus, Nature 313 (1985) 636-637. (Pubitemid 15172464)
24. R. Yarchoan, R.W. Klecker, K.J. Weinhold, P.D. Markham, H.K. Lyerly, D.T. Durack, et al., Administration of 3-azido-3-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex, Lancet 1 (1986) 575-580. (Pubitemid 16138382)
25. M.A. Fischl, D.D. Richman, M.H. Grieco, M.S. Gottlieb, P.A. Volberding, O.L. Laskin, et al., The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial, N. Engl. J. Med. 317 (1987) 185-191. (Pubitemid 17114872)
26. B.A. Larder, G. Darby, D.D. Richman, HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy, Science 243 (1989) 1731-1734. (Pubitemid 19106971)
27. B.D. Preston, B.J. Poiesz, L.A. Loeb, Fidelity of HIV-1 reverse transcriptase, Science 242 (1988) 1168-1171. (Pubitemid 19007042)
28. J.D. Roberts, K. Bebenek, T.A. Kunkel, The accuracy of reverse transcriptase from HIV-1, Science 242 (1988) 1171-1173. (Pubitemid 19007043)
29. B.A. Larder, S.D. Kemp, Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT), Science 246 (1989) 1155-1158. (Pubitemid 20012773)
30. WHO, HIV Seropositivity and AIDS Prevention and Control - Report on a WHO Meeting, 1989, 5 pp.
31. V.J. Merluzzi, K.D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J.C. Wu, et al., Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor, Science 250 (1990) 1411-1413. (Pubitemid 120031860)
32. L. Toji, S.S. Cohen, The enzymatic termination of polydeoxynucleotides by 2-,3-dideoxyadenosine triphosphate, Proc. Natl. Acad. Sci. U. S. A. 63 (1969) 871-877.
33. H. Mitsuya, K.J. Weinhold, P.A. Furman, M.H. St Clair, S.N. Lehrman, R.C. Gallo, et al., 3-Azido-3-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro, Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 7096-7100. (Pubitemid 16209699)
34. J.W. Mellors, G.E. Dutschman, G.J. Im, E. Tramontano, S.R. Winkler, Y.C. Cheng, In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase, Mol. Pharmacol. 41 (1992) 446-451.
35. B.A. Larder, S.D. Kemp, D.J. Purifoy, Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity, Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 4803-4807.
36. R. Rooke, M. Tremblay, H. Soudeyns, L. DeStephano, X.J. Yao, M. Fanning, et al., Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group, AIDS 3 (1989) 411-415. (Pubitemid 19210445)
37. B.A. Larder, K.E. Coates, S.D. Kemp, Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture, J. Virol. 65 (1991) 5232-5236.
38. Z. Debyser, K. De Vreese, P.P. Knops-Gerrits, V. Baekelandt, R. Bhikhabhai, B. Strandberg, et al., Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1- specific reverse transcriptase inhibitors, Mol. Pharmacol. 43 (1993) 521-526. (Pubitemid 23112728)
39. M.E. Cong, W. Heneine, J.G. Garcia-Lerma, The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions, J. Virol. 81 (2007) 3037-3041. (Pubitemid 46447070)
40. D.V. Havlir, S. Eastman, A. Gamst, D.D. Richman, Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients, J. Virol. 70 (1996) 7894-7899. (Pubitemid 26339097)
41. E.A. Soares, A.F. Santos, T.M. Sousa, E. Sprinz, A.M. Martinez, J. Silveira, et al., Differential drug resistance acquisition in HIV-1 of subtypes B and C, PLoS One 2 (2007) e730.
42. J.B. Jackson, G. Becker-Pergola, L.A. Guay, P. Musoke, M. Mracna, M.G. Fowler, et al., Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission, AIDS 14 (2000) F111-F115.
43. R. Yarchoan, H. Mitsuya, R.V. Thomas, J.M. Pluda, N.R. Hartman, C.F. Perno, et al., In vivo activity against HIV and favorable toxicity profile of 2-,3- dideoxyinosine, Science 245 (1989) 412-415. (Pubitemid 19203366)
44. H. Mitsuya, S. Broder, Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy- associated virus (HTLV-III/LAV) by 2-,3-dideoxynucleosides, Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 1911-1915. (Pubitemid 16018673)
45. M.H. St Clair, J.L. Martin, G. Tudor-Williams, M.C. Bach, C.L. Vavro, D.M. King, et al., Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase, Science 253 (1991) 1557-1559. (Pubitemid 21917313)
46. A.J. Japour, P.A. Chatis, H.A. Eigenrauch, C.S. Crumpacker, Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA·RNA hybridization, Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 3092-3096. (Pubitemid 21916565)
47. B.A. Larder, B. Chesebro, D.D. Richman, Susceptibilities of zidovudinesusceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay, Antimicrob. Agents Chemother. 34 (1990) 436-441. (Pubitemid 20068667)
48. R. Rooke, M.A. Parniak, M. Tremblay, H. Soudeyns, X.G. Li, Q. Gao, et al., Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs, Antimicrob. Agents Chemother. 35 (1991) 988-991.
49. J.E. Fitzgibbon, R.M. Howell, C.A. Haberzettl, S.J. Sperber, D.J. Gocke, D.T. Dubin, Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2-,3-dideoxycytidine, Antimicrob. Agents Chemother. 36 (1992) 153-157.
50. H. Mitsuya, R.F. Jarrett, M. Matsukura, F. Di Marzo Veronese, A.L. DeVico, M.G. Sarngadharan, et al., Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2-,3- dideoxynucleosides in vitro, Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 2033-2037. (Pubitemid 17054144)
51. R. Yarchoan, C.F. Perno, R.V. Thomas, R.W. Klecker, J.P. Allain, R.J. Wills, et al., Phase I studies of 2-,3-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT), Lancet 1 (1988) 76-81.
52. S.A. Spector, D. Ripley, K. Hsia, Human immunodeficiency virus inhibition is prolonged by 3-azido-3-deoxythymidine alternating with 2-,3-dideoxycytidine compared with 3-azido-3-deoxythymidine alone, Antimicrob. Agents Chemother. 33 (1989) 920-923. (Pubitemid 19146584)
53. M. Baba, R. Pauwels, J. Balzarini, P. Herdewijn, E. De Clercq, J. Desmyter, Ribavirin antagonizes inhibitory effects of pyrimidine 2-,3-dideoxynucleosides but enhances inhibitory effects of purine 2-,3-dideoxynucleosides on replication of human immunodeficiency virus in vitro, Antimicrob. Agents Chemother. 31 (1987) 1613-1617. (Pubitemid 17140823)
54. T.C. Meng, M.A. Fischl, A.M. Boota, S.A. Spector, D. Bennett, Y. Bassiakos, et al., Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study, Ann. Intern. Med. 116 (1992) 13-20.
55. D.D. Richman, T.C. Meng, S.A. Spector, M.A. Fischl, L. Resnick, S. Lai, Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus, J. Acquir. Immune Defic. Syndr. 7 (1994) 135-138. (Pubitemid 24052347)
56. B.A. Larder, A. Kohli, S. Bloor, S.D. Kemp, P.R. Harrigan, R.T. Schooley, et al., Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2-,3-dideoxyinosine or AZT plus 2-,3-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group, J. Virol. 70 (1996) 5922-5929. (Pubitemid 26266805)
57. D.D. Ho, A.U. Neumann, A.S. Perelson, W. Chen, J.M. Leonard, M. Markowitz, Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection, Nature 373 (1995) 123-126.
58. J.W. Mellors, C.R. Rinaldo Jr., P. Gupta, R.M. White, J.A. Todd, L.A. Kingsley, Prognosis in HIV-1 infection predicted by the quantity of virus in plasma, Science 272 (1996) 1167-1170. (Pubitemid 26001148)
59. Q. Gao, Z. Gu, M.A. Parniak, J. Cameron, N. Cammack, C. Boucher, et al., The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2-,3-dideoxyinosine and 2-,3-dideoxycytidine confers high-level resistance to the (?) enantiomer of 2-,3-dideoxy-3-thiacytidine, Antimicrob. Agents Chemother. 37 (1993) 1390-1392. (Pubitemid 23166750)
60. R. Schuurman, M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, et al., Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC), J. Infect. Dis. 171 (1995) 1411-1419.
61. Z. Gu, Q. Gao, X. Li, M.A. Parniak, M.A. Wainberg, Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2-,3-dideoxyinosine and 2-,3-dideoxycytidine, J. Virol. 66 (1992) 7128-7135.
62. M. Tisdale, S.D. Kemp, N.R. Parry, B.A. Larder, Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase, Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 5653-5656. (Pubitemid 23176219)
63. J.J. Eron Jr., J.A. Bartlett, J.L. Santana, N.C. Bellos, J. Johnson, A. Keller, et al., Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation, J. Acquir. Immune Defic. Syndr. 37 (2004) 1581-1583. (Pubitemid 39658197)
64. J.E. Gallant, The M184V mutation: what it does, how to prevent it, and what to do with it when it's there, AIDS Read. 16 (2006) 556-559. (Pubitemid 44646033)
65. R.A. Kramer, M.D. Schaber, A.M. Skalka, K. Ganguly, F. Wong-Staal, E.P. Reddy, HTLV-III gag protein is processed in yeast cells by the virus pol-protease, Science 231 (1986) 1580-1584. (Pubitemid 16050731)
66. M.C. Graves, J.J. Lim, E.P. Heimer, R.A. Kramer, An 11-kDa form of human immunodeficiency virus protease expressed in Escherichia coli is sufficient for enzymatic activity, Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 2449-2453.
67. N.E. Kohl, E.A. Emini, W.A. Schleif, L.J. Davis, J.C. Heimbach, R.A. Dixon, et al., Active human immunodeficiency virus protease is required for viral infectivity, Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 4686-4690.
68. S.F. Le Grice, J. Mills, J. Mous, Active site mutagenesis of the AIDS virus protease and its alleviation by trans complementation, EMBO J. 7 (1988) 2547-2553.
69. C. Flexner, S.S. Broyles, P. Earl, S. Chakrabarti, B. Moss, Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses, Virology 166 (1988) 339-349.
70. V. Karacostas, K. Nagashima, M.A. Gonda, B. Moss, Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector, Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 8964-8967. (Pubitemid 20010346)
71. L.E. Henderson, M.A. Bowers, R.C. Sowder 2nd, S.A. Serabyn, D.G. Johnson, J.W. Bess Jr., et al., Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processings, and complete amino acid sequences, J. Virol. 66 (1992) 1856-1865.
72. C. Debouck, The HIV-1 protease as a therapeutic target for AIDS, AIDS Res. Hum. Retroviruses 8 (1992) 153-164.
73. H.A. Overton, D.J. McMillan, S.J. Gridley, J. Brenner, S. Redshaw, J.S. Mills, Effect of two novel inhibitors of the human immunodeficiency virus protease on the maturation of the HIV gag and gag-pol polyproteins, Virology 179 (1990) 508-511. (Pubitemid 20354368)
74. N.A. Roberts, J.A. Martin, D. Kinchington, A.V. Broadhurst, J.C. Craig, I.B. Duncan, et al., Rational design of peptide-based HIV proteinase inhibitors, Science 248 (1990) 358-361.
75. J.H. Condra, W.A. Schleif, O.M. Blahy, L.J. Gabryelski, D.J. Graham, J.C. Quintero, et al., In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors, Nature 374 (1995) 569-571.
76. M.J. Otto, S. Garber, D.L. Winslow, C.D. Reid, P. Aldrich, P.K. Jadhav, et al., In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease, Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 7543-7547. (Pubitemid 23249986)
77. M.A. el-Farrash, M.J. Kuroda, T. Kitazaki, T. Masuda, K. Kato, M. Hatanaka, et al., Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor, J. Virol. 68 (1994) 233-239.
78. D.D. Ho, T. Toyoshima, H. Mo, D.J. Kempf, D. Norbeck, C.M. Chen, et al., Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor, J. Virol. 68 (1994) 2016-2020. (Pubitemid 24065777)
79. A.K. Patick, H. Mo, M. Markowitz, K. Appelt, B. Wu, L. Musick, et al., Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease, Antimicrob. Agents Chemother. 40 (1996) 292-297. (Pubitemid 26053135)
80. R.F. Schinazi, B.A. Larder, J.W. Mellors, Mutations in retroviral genes associated with drug resistance, in: International Antiviral News, International Medical Press, 1996, pp. 95-107. (Pubitemid 26340526)
81. A. Molla, M. Korneyeva, Q. Gao, S. Vasavanonda, P.J. Schipper, H.M. Mo, et al., Ordered accumulation of mutations in HIV protease confers resistance to ritonavir, Nat. Med. 2 (1996) 760-766. (Pubitemid 26225091)
82. D.A. Donahue, R.D. Sloan, B.D. Kuhl, T. Bar-Magen, S.M. Schader, M.A. Wainberg, Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture, Antimicrob. Agents Chemother. 54 (2010) 1047-1054.
83. A.R. Sedaghat, J.B. Dinoso, L. Shen, C.O. Wilke, R.F. Siliciano, Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 4832-4837. (Pubitemid 351753832)
84. M.A. Jhaveri, S.R. Browning, H. Bush, A. Thornton, R.N. Greenberg, Comparison of 3-drug versus 4-drug and PI versus non-PI combinations as initial HAART: experience from 1998 to 2007, J. Int. Assoc. Physicians AIDS Care (Chic.) 8 (2009) 299-307.
85. D.D. Ho, Time to hit HIV early and hard, N. Engl. J. Med. 333 (1995) 450-451.
86. S. Emery, J.A. Neuhaus, A.N. Phillips, A. Babiker, C.J. Cohen, J.M. Gatell, et al., Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study, J. Infect. Dis. 197 (2008) 1133-1144. (Pubitemid 351590049)
87. J.A. Sterne, M. May, D. Costagliola, F. de Wolf, A.N. Phillips, R. Harris, et al., Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies, Lancet 373 (2009) 1352-1363.
88. M.S. Cohen, Y.Q. Chen, M. McCauley, T. Gamble, M.C. Hosseinipour, N. Kumarasamy, et al., Prevention of HIV-1 infection with early antiretroviral therapy, N. Engl. J. Med. 365 (2011) 493-505.
89. R.E. Haaland, P.A. Hawkins, J. Salazar-Gonzalez, A. Johnson, A. Tichacek, E. Karita, et al., Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1, PLoS Pathog. 5 (2009) e1000274.
90. M.R. Abrahams, J.A. Anderson, E.E. Giorgi, C. Seoighe, K. Mlisana, L.H. Ping, et al., Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants, J. Virol. 83 (2009) 3556-3567.
91. T. Zhu, H. Mo, N. Wang, D.S. Nam, Y. Cao, R.A. Koup, et al., Genotypic and phenotypic characterization of HIV-1 patients with primary infection, Science 261 (1993) 1179-1181. (Pubitemid 23300886)
92. L.Q. Zhang, P. MacKenzie, A. Cleland, E.C. Holmes, A.J. Brown, P. Simmonds, Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection, J. Virol. 67 (1993) 3345-3356. (Pubitemid 23143709)
93. S. Pang, Y. Shlesinger, E.S. Daar, T. Moudgil, D.D. Ho, I.S. Chen, Rapid generation of sequence variation during primary HIV-1 infection, AIDS 6 (1992) 453-460.
94. G.H. Learn, D. Muthui, S.J. Brodie, T. Zhu, K. Diem, J.I. Mullins, et al., Virus population homogenization following acute human immunodeficiency virus type 1 infection, J. Virol. 76 (2002) 11953-11959. (Pubitemid 35304295)
95. Q. Abdool Karim, S.S. Abdool Karim, J.A. Frohlich, A.C. Grobler, C. Baxter, L.E. Mansoor, et al., Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women, Science 329 (2010) 1168-1174.
96. S. Vella, L. Palmisano, The global status of resistance to antiretroviral drugs, Clin. Infect. Dis. 41 (Suppl. 4) (2005) S239-S246. (Pubitemid 41099618)
97. A.M. Wensing, D.A. van de Vijver, G. Angarano, B. Asjo, C. Balotta, E. Boeri, et al., Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management, J. Infect. Dis. 192 (2005) 958-966. (Pubitemid 41266791)
98. H.S. Weinstock, I. Zaidi, W. Heneine, D. Bennett, J.G. Garcia-Lerma, J.M. Douglas Jr., et al., The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities, J. Infect. Dis. 189 (2004) 2174-2180. (Pubitemid 38757188)
99. S.M. Schader, S.P. Colby-Germinario, J.R. Schachter, H. Xu, M.A. Wainberg, Synergy against drug resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination, AIDS 25 (2011) 1585-1594.
100. S. Subbarao, R.A. Otten, A. Ramos, C. Kim, E. Jackson, M. Monsour, et al., Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges, J. Infect. Dis. 194 (2006) 904-911. (Pubitemid 44454075)
101. J.G. Garcia-Lerma, R.A. Otten, S.H. Qari, E. Jackson, M.E. Cong, S. Masciotra, et al., Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir, PLoS Med. 5 (2008) e28.
102. J.G. Garcia-Lerma, M.E. Cong, J. Mitchell, A.S. Youngpairoj, Q. Zheng, S. Masciotra, et al., Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection, Sci. Transl. Med. 2 (2010) 14ra14.
103. N. Prada, B. Davis, P. Jean-Pierre, M. La Roche, F.M. Duh, M. Carrington, et al., Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course, J. Acquir. Immune Defic. Syndr. 49 (2008) 117-122.
104. U.L. Abbas, G. Hood, A.W. Wetzel, J.W. Mellors, Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP), PLoS One 6 (2011) e18165.
105. D.A. van de Vijver, I. Derdelinckx, C.A. Boucher, Circulating HIV, type 1 drug resistance will have limited impact on the effectiveness of preexposure prophylaxis among young women in Zimbabwe, J. Infect. Dis. 199 (2009) 1310-1317.
106. V. Supervie, J.G. Garcia-Lerma, W. Heneine, S. Blower, HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis, Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 12381-12386.